Tom Richardson

Company: Merck & Co

Job title: Principal Pathologist & Lead - Companion Diagnostic

Bio:

Tom is a board-certified pathologist and translational scientist with extensive experience in oncology research, biomarkers, clinical diagnostics, experimental pathology, and immunology. He is a Pathologist in the Companion Diagnostics development team, Oncology Clinical Research, at Merck & Co., Inc., where he leads the Digital Pathology Working Group and leads digital pathology clinical diagnostic development across the pipeline. Prior to his role in the pharmaceutical industry, he practiced breast pathology and cytopathology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, and led translational biomarker and clinical diagnostic research projects in breast cancer. He is based in Boston, Massachusetts.

Seminars:

Translating Discovery to Companion Diagnostics for Antibody-Drug Conjugates Through AI-Driven Image Analysis 9:30 am

Digital pathology offers exciting opportunities for novel biomarker discovery, development, and clinical diagnostics Efficacy of antibody-drug conjugates may depend on target antigen expression or other histopathologic features that can be developed as a predictive signature Drug developers are eager to identify digital pathology solutions to optimally support pipelines and patient identificationRead more

day: Conference Day One

Panel Discussion: Driving Patient Selection with Digital Pathology for Streamlined Clinical Trials 9:30 am

How can digital pathology improve the identification and stratification of patients for biomarker-driven therapies, and where is it already making a measurable impact? What steps should biopharma take to integrate digital pathology into trial design early, so it meaningfully contributes to patient enrichment, rather than becoming an afterthought? What are the key considerations when validating…Read more

day: Conference Day Two